1: Acta Endocrinol Suppl (Copenh) 1985;271:19-30 Related Articles, Books
Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers.
Wijnand HP, Bosch AM, Donker CW.
Nandrolone decanoate (Deca-Durabolin) was injected intramuscularly into healthy volunteers. One group of females received one injection of 100 mg and three groups of males received one injection of 200 mg, two repeat injections of 100 mg or four repeat injections of 50 mg respectively. The serum levels of nandrolone (19-nortestosterone) were determined by radioimmunoassay and used to estimate pharmacokinetic parameters. The following pharmacokinetic parameters were found: a mean half-life of 6 days for the release of the ester from the muscular injection depot into the general circulation; a mean half-life of 4.3 h for the combined processes of hydrolysis of nandrolone decanoate and of distribution and elimination of nandrolone; a mean nandrolone serum clearance of 1.55 1 X h-1 X kg-1. The half-life of hydrolysis of nandrolone decanoate in serum was of the order of one hour or less. The data are consistent with linear kinetics.
PMID: 3865478 [PubMed - indexed for MEDLINE]
---------------------------------------------------------------------------
Ha???? Now, according to this one, Decanoate's half life is 6.5 days also. WTF??????
In study on Nandrolones( Decanoate and PP) plasma concentration reterned to normal in 13 days for PP, and 20 days for Decanoate, which gives 10 days half life for Decanoate.
Very inconclusive data!
Some good explanation on how ester work from Nandrolone study:
"). Experimental studies suggest that absorption rates are predicted by the oil/water partition coefficients (or hydrophobicity) and that the oil vehicle is absorbed more slowly than the androgen ester (Tanaka et al., 1974 ). In humans, the very short propionate (three-carbon aliphatic) ester of testosterone has distinctly shorter duration of action than esters with longer (seven- or eight-carbon) side-chains (Nieschlag et al., 1976 ; Schulte-Beerbuhl and Nieschlag, 1980 ; Schurmeyer and Nieschlag, 1984 ; Belkien et al., 1985 ; Fujioka et al., 1986 ). More subtle changes in side-chain ester structure have proven ineffective in altering human clinical pharmacokinetics, because substitution of a linear aliphatic side-chain of seven carbons (enanthate) with either a saturated, cyclized, seven-carbon aliphatic chain (cyclohexanecarboxylate) (Schurmeyer and Nieschlag, 1984 ) or a linear, aliphatic, eight-carbon chain (cypionate) (Schulte-Beerbuhl and Nieschlag, 1980 ) resulted in virtually unchanged kinetics. Wider variation in ester side-chain chemistry to include greater chain length and/or aromatic ring structures is a more effective determinant of ester pharmacokinetics, because nandrolone hexoxyphenylpropionate ester (aromatic ring with 18 carbons) had far better depot properties, with a prolonged and retarded release profile, compared with the decanoate (aliphatic chain with 10 carbons) (Belkien et al., 1985 ). The present study indicates that a side-chain ester consisting of a 10-carbon aliphatic chain(Decanoate) has better depot properties than a nine-carbon chain including an aromatic ring(Phenylpropionate)."